Merck/Schering’s Vytorin Clears FDA: Price Is 22% Discount To Lipitor

Merck/Schering-Plough's cholesterol-lowering agent Vytorin will carry a wholesale acquisition cost that is a 22% discount to the three highest doses of Pfizer's Lipitor

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet